表紙
市場調査レポート

B型肝炎:パイプライン製品の分析

Hepatitis B - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232823
出版日 ページ情報 英文 386 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
B型肝炎:パイプライン製品の分析 Hepatitis B - Pipeline Review, H1 2016
出版日: 2016年05月31日 ページ情報: 英文 386 Pages
概要

B型肝炎は、命を脅かす危険性がある肝臓の感染症です。B型肝炎ウイルスは、黄疸、暗色尿、重度の倦怠感、悪心、嘔吐、腹痛を伴う急性疾患の原因となることがあります。B型肝炎に罹患するリスク因子としては、老齢化、重度の腎臓病、血友病、注射針の使いまわし、B型肝炎に感染している母親からの誕生などが挙げられます。

当レポートでは、B型肝炎治療薬の開発状況について調査しており、パイプライン製品の概要、治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

  • 調査範囲

B型肝炎の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

B型肝炎:企業で開発中の治療薬

B型肝炎:大学/機関で研究中の治療薬

B型肝炎:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

B型肝炎:企業で開発中の製品

B型肝炎:大学/機関で研究中の製品

B型肝炎の治療薬開発に従事している企業

  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Tekmira Pharmaceuticals Corp.
  • Isis Pharmaceuticals, Inc.
  • Gilead Sciences, Inc.
  • Celltrion, Inc.
  • Biological E. Limited
  • Ildong Pharmaceutical Co., Ltd.
  • SK Chemicals Co., Ltd.
  • Aduro BioTech, Inc.
  • CEL-SCI Corporation
  • Arrowhead Research Corporation
  • Ligand Pharmaceuticals, Inc.
  • Benitec Biopharma Limited
  • BioDiem Ltd
  • Dynavax Technologies Corporation
  • Transgene SA
  • Bukwang Pharmaceutical Co., Ltd.
  • Green Cross Corporation
  • Mologen AG
  • LG Life Sciences, Ltd.
  • Uni-Bio Science Group Ltd.
  • Panacea Biotec Limited
  • ChronTech Pharma AB
  • NeuroVive Pharmaceutical AB
  • Colby Pharmaceutical Company
  • Scynexis, Inc.
  • Mucosis B.V.
  • Therametrics holding AG
  • AiCuris GmbH & Co. KG
  • Amarna Therapeutics B.V.
  • TetraLogic Pharmaceuticals
  • Romark Laboratories, L.C.
  • REPLICor Inc.
  • Immune Targeting Systems (ITS) Ltd.
  • Sinovac Biotech Ltd.
  • Genexine, Inc.
  • GeneCure LLC
  • NanoBio Corporation
  • Bolder Biotechnology, Inc.
  • Immunovaccine, Inc.
  • Seek
  • Vaxart, Inc.
  • PharmaEssentia Corporation
  • iQur Ltd.
  • RFS Pharma, LLC
  • Vaxine Pty Ltd
  • VLP Biotech, Inc.
  • Indian Immunologicals Limited
  • AUS Bio Limited
  • Beijing Minhai Biotechnology Co., Ltd
  • AltraVax Inc.
  • Sanofi Pasteur MSD SNC
  • SomaGenics Inc.
  • Spring Bank Pharmaceuticals, Inc.
  • Novira Therapeutics, Inc.
  • Leukocare AG
  • Nuron Biotech, Inc.
  • Big DNA Ltd.
  • Hepacyl Therapeutics, SL
  • Chongqing Zhifei Biological Products Co., Ltd.
  • Inbiopro Solutions Pvt. Ltd.
  • Chiasma, Inc.
  • RAPID Pharmaceuticals AG
  • Humabs BioMed SA
  • HEC Pharm Co., Ltd.
  • AlphaMab Co., Ltd
  • GlobalAcorn

B型肝炎:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • tenofovir disoproxil fumarate
  • clevudine
  • besifovir
  • NASVACワクチン
  • DtwP-HB-Hib (liq)ワクチン
  • Hepabulin
  • Novaferon
  • DTwP-HBV-Hib
  • tenofovir alafenamide
  • 組換えB型肝炎ワクチン (Hansenula)
  • Hexavalent DTwP-Hepb-Hib-IPVワクチン
  • SCY-635
  • peginterferon alfa-2b
  • 治療用B型肝炎ワクチン
  • GSK-217744
  • peginterferon lambda-1a
  • ARC-520
  • Myrcludex-B
  • GS-4774
  • GSK-2231392A
  • GLS-4
  • REP-9-AC
  • REP-9-AC'
  • interferon alfa-2a
  • HPDCs-T Immune Therapy
  • pradefovir mesylate
  • HB-110
  • GS-9620
  • SB-9200
  • 予防用B型肝炎ワクチン
  • GC-1102
  • Creaferon
  • RG-7795
  • W28F
  • NVR-1221
  • ISIS-HBVRx
  • RG-7863
  • NVR-3778
  • KN-003
  • amdoxovir
  • CEL-1000
  • birinapant
  • RM-5038
  • MGN-1333
  • Lm-HBV
  • AGX-1009
  • IBPB-006-IA
  • Hepbarna
  • 治療用B型肝炎ワクチン
  • RAP-164
  • TG-1050
  • cTP-5
  • NU-500
  • Interferon Alpha
  • ChronVac-B
  • BC-556
  • SCY-575
  • P60 Inhibitor Peptide
  • INO-1800
  • acALY18
  • 肝炎用ワクチン
  • interferon alfa-2bバイオシミラー
  • Hepatacore
  • RNAiオリゴヌクレオチド
  • AIC-649
  • MAb Against HBV
  • DPT-H-HiBワクチン
  • HepB-nRNA
  • TKM-HBV
  • Immunoplex-HepB
  • BDNA-001
  • DasKloster-0039-01
  • BBT-012
  • JVRS-100 + HBVワクチン
  • CT-P24
  • PC-2000
  • FP-02
  • DVR-23
  • GA-5-NM-HBV
  • DTwP-Hep B-IPV-Hib
  • Hep B-IPV-Hib
  • モノクローナル抗体、など

B型肝炎:最近のパイプライン動向

B型肝炎:休止中のプロジェクト

B型肝炎:開発が中止された製品

B型肝炎:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7979IDB

Summary

Global Markets Direct's, 'Hepatitis B - Pipeline Review, H1 2016', provides an overview of the Hepatitis B pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatitis B, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hepatitis B
  • The report reviews pipeline therapeutics for Hepatitis B by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hepatitis B therapeutics and enlists all their major and minor projects
  • The report assesses Hepatitis B therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hepatitis B

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hepatitis B
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Hepatitis B Overview
  • Therapeutics Development
  • Hepatitis B - Therapeutics under Development by Companies
  • Hepatitis B - Therapeutics under Investigation by Universities/Institutes
  • Hepatitis B - Pipeline Products Glance
  • Hepatitis B - Products under Development by Companies
  • Hepatitis B - Products under Investigation by Universities/Institutes
  • Hepatitis B - Companies Involved in Therapeutics Development
  • Hepatitis B - Therapeutics Assessment
  • Drug Profiles
  • Hepatitis B - Recent Pipeline Updates
  • Hepatitis B - Dormant Projects
  • Hepatitis B - Discontinued Products
  • Hepatitis B - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Hepatitis B, H1 2016
  • Number of Products under Development for Hepatitis B - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Hepatitis B - Pipeline by Abivax S.A., H1 2016
  • Hepatitis B - Pipeline by AiCuris GmbH & Co. KG, H1 2016
  • Hepatitis B - Pipeline by AIMM Therapeutics B.V., H1 2016
  • Hepatitis B - Pipeline by Akshaya Bio Inc., H1 2016
  • Hepatitis B - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016
  • Hepatitis B - Pipeline by AlphaMab Co., Ltd, H1 2016
  • Hepatitis B - Pipeline by Altimmune, Inc., H1 2016
  • Hepatitis B - Pipeline by Altravax, Inc., H1 2016
  • Hepatitis B - Pipeline by Amarna Therapeutics B.V., H1 2016
  • Hepatitis B - Pipeline by Arbutus Biopharma Corporation, H1 2016
  • Hepatitis B - Pipeline by Arrowhead Pharmaceuticals, Inc., H1 2016
  • Hepatitis B - Pipeline by Assembly Biosciences, Inc., H1 2016
  • Hepatitis B - Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H1 2016
  • Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016
  • Hepatitis B - Pipeline by Benitec Biopharma Limited, H1 2016
  • Hepatitis B - Pipeline by BioDiem Ltd, H1 2016
  • Hepatitis B - Pipeline by Biogenomics Limited, H1 2016
  • Hepatitis B - Pipeline by Biological E. Limited, H1 2016
  • Hepatitis B - Pipeline by BioStar Pharmaceuticals, Inc., H1 2016
  • Hepatitis B - Pipeline by Bolder Biotechnology, Inc., H1 2016
  • Hepatitis B - Pipeline by Bukwang Pharm.Co., Ltd., H1 2016
  • Hepatitis B - Pipeline by CaroGen Corporation, H1 2016
  • Hepatitis B - Pipeline by Celltrion, Inc., H1 2016
  • Hepatitis B - Pipeline by Chimerix, Inc., H1 2016
  • Hepatitis B - Pipeline by ChronTech Pharma AB, H1 2016
  • Hepatitis B - Pipeline by Cocrystal Pharma, Inc., H1 2016
  • Hepatitis B - Pipeline by ContraVir Pharmaceuticals, Inc., H1 2016
  • Hepatitis B - Pipeline by CyTuVax B.V., H1 2016
  • Hepatitis B - Pipeline by Dynavax Technologies Corporation, H1 2016
  • Hepatitis B - Pipeline by Ensemble Therapeutics Corporation, H1 2016
  • Hepatitis B - Pipeline by Enyo Pharma S.A.S., H1 2016
  • Hepatitis B - Pipeline by eTheRNA Immunotherapies NV, H1 2016
  • Hepatitis B - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Hepatitis B - Pipeline by GeneCure LLC, H1 2016
  • Hepatitis B - Pipeline by Gilead Sciences, Inc., H1 2016
  • Hepatitis B - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Hepatitis B - Pipeline by Green Cross Corporation, H1 2016
  • Hepatitis B - Pipeline by HEC Pharm Co., Ltd., H1 2016
  • Hepatitis B - Pipeline by Humabs BioMed SA, H1 2016
  • Hepatitis B - Pipeline by Immunotope, Inc., H1 2016
  • Hepatitis B - Pipeline by Immunovaccine, Inc., H1 2016
  • Hepatitis B - Pipeline by Indian Immunologicals Limited, H1 2016
  • Hepatitis B - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016
  • Hepatitis B - Pipeline by ISA Pharmaceuticals B.V., H1 2016
  • Hepatitis B - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2016
  • Hepatitis B - Pipeline by Johnson & Johnson, H1 2016
  • Hepatitis B - Pipeline by Kineta, Inc., H1 2016
  • Hepatitis B - Pipeline by Kuros Biosciences AG, H1 2016
  • Hepatitis B - Pipeline by Leukocare AG, H1 2016
  • Hepatitis B - Pipeline by LG Life Science LTD., H1 2016
  • Hepatitis B - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016
  • Hepatitis B - Pipeline by Mologen AG, H1 2016
  • Hepatitis B - Pipeline by Mucosis B.V., H1 2016
  • Hepatitis B - Pipeline by MultiCell Technologies, Inc., H1 2016
  • Hepatitis B - Pipeline by Panacea Biotec Limited, H1 2016
  • Hepatitis B - Pipeline by Pfenex Inc., H1 2016
  • Hepatitis B - Pipeline by PharmaEssentia Corporation, H1 2016
  • Hepatitis B - Pipeline by Profectus BioSciences, Inc., H1 2016
  • Hepatitis B - Pipeline by Redx Pharma Plc, H1 2016
  • Hepatitis B - Pipeline by REPLICor Inc., H1 2016
  • Hepatitis B - Pipeline by Sanofi Pasteur SA, H1 2016
  • Hepatitis B - Pipeline by SEEK Group, H1 2016
  • Hepatitis B - Pipeline by Sinovac Biotech Ltd., H1 2016
  • Hepatitis B - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2016
  • Hepatitis B - Pipeline by Staidson (Beijing) Biopharmaceuticals Co., Ltd., H1 2016
  • Hepatitis B - Pipeline by TCM Biotech International Corp, H1 2016
  • Hepatitis B - Pipeline by TetraLogic Pharmaceuticals, H1 2016
  • Hepatitis B - Pipeline by TGV-Laboratories, H1 2016
  • Hepatitis B - Pipeline by Theravectys SA, H1 2016
  • Hepatitis B - Pipeline by Tomegavax, Inc., H1 2016
  • Hepatitis B - Pipeline by Transgene SA, H1 2016
  • Hepatitis B - Pipeline by UAB Profarma, H1 2016
  • Hepatitis B - Pipeline by Vaxine Pty Ltd, H1 2016
  • Hepatitis B - Pipeline by Viriom Ltd., H1 2016
  • Hepatitis B - Pipeline by VLP Biotech, Inc., H1 2016
  • Hepatitis B - Pipeline by Zydus Cadila Healthcare Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Hepatitis B Therapeutics - Recent Pipeline Updates, H1 2016
  • Hepatitis B - Dormant Projects, H1 2016
  • Hepatitis B - Dormant Projects (Contd..1), H1 2016
  • Hepatitis B - Dormant Projects (Contd..2), H1 2016
  • Hepatitis B - Dormant Projects (Contd..3), H1 2016
  • Hepatitis B - Dormant Projects (Contd..4), H1 2016
  • Hepatitis B - Dormant Projects (Contd..5), H1 2016
  • Hepatitis B - Dormant Projects (Contd..6), H1 2016
  • Hepatitis B - Dormant Projects (Contd..7), H1 2016
  • Hepatitis B - Dormant Projects (Contd..8), H1 2016
  • Hepatitis B - Dormant Projects (Contd..9), H1 2016
  • Hepatitis B - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Hepatitis B, H1 2016
  • Number of Products under Development for Hepatitis B - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top